Unrecognized hypocalcaemia
The paper by Bellamy and Kendall-Taylor (December 1995 jRSM, pp 690-1), which described a patient with hypoparathyroidism 30 years after almost total thyroidectomy, reminded Cassar (May 1996 jRSM, P 299) of a patient whose hypocalcaemia derived from coeliac disease. I, in my tum was reminded of a patient whose hypocalcaemia had followed partial gastrectomy 14 years before, which had led to vitamin 0 deficiency and osteomalacia from malabsorption with steatorrhoea'. With these, however, there was thirst and polyuria, with hypophosphataemia, raised alkaline phosphatase levels, a renal stone and osteitis fibrosa, diagnosed as secondary hyperparathyroidism because of the hypocalcaemia. On treatment with vitamin D she developed hypercalcaemia that persisted, leading to the removal of a parathyroid adenoma. Vitamin D deficiency had caused hypocalcaemia and masked primary hyperparathyroidism by rendering the plasma-calcium-raising action of parathyroid hormone ineffective.
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Prenatal screening vouchers
Professor Lilford and Dr Thornton (March 1996jRSM, pp 130-1) rightly point out that we do not know the best methods of allocating resources within the National Health Service and that some secondary preventive procedures, such as prenatal screening, are not taken up by all those who would be entitled to them. They go on to suggest that vouchers for prenatal screening are the only option to prevent those who do not want to use this service from subsidizing those who do. While. their arguments are logical in themselves, there are several pitfalls that would make such a scheme unworkable, cost inefficient, unfair and unethical.
Lilford and Thornton suggest that the value of the voucher should be adjusted to be equivalent to the cost of the test to the health service, 'taking into acount the health service savings from preventing handicap'. With this approach the voucher would have a negative value if the test in question were cost effective as far as total health service costs were concerned. Determining the value of the voucher would be difficult, since different health care providers might offer different packages of prenatal testing. Even identical packages could have different values depending on the qualifications and expertise of those who are performing the tests. As health care providers contract out more procedures (such as pathological analysis) the differences in the value of vouchers are likely to become greater.
Calculating the savings for care providers would be equally difficult since the costs of providing a health care service are not proportional to the number of individual services provided. Personnel costs account for the highest proportion of expenses of any health care provider and unless personnel are reduced the savings to the health service from not doing a test are likely to be smaller than the costs of administering the voucher system. Reducing personnel may not be an option as some prenatal screening should be provided by the health service even if it is not taken up by the majority of potential users.
Lilford and Thornton rightly state that not all health care providers or users can agree on the value of a test. To assign a monetary value to it might be even more difficult-at the very least it could be an expensive procedure.
To further analyse the appropriateness of vouchers for prenatal testing one has to assume that a monetary value could be assigned to the vouchers and that regional differences could be overcome by an elaborate (and expensive) accounting system. The value of the voucher would constitute a certain percentage of the expendable income of an individual family. It might be equivalent to 3 weeks' expendable income in a poor family or less than I days' expendable income in a rich family. The cost, adjusted for family income, of having a test would therefore be higher for a low income family than for a high income family.
The ethical problems of a voucher scheme would be extremely complex. Assuming a health service user had converted the voucher to cash, would the mother and her child then still be entitled to any potential intervention which could have been prevented had the voucher been used for a prenatal screening test? Example: a mother decides to cash in her antibody test vouchers. At 32 weeks an ultrasound scan is performed for suspected polyhydramnios and fetal hydrops is diagnosed. Will the fetus and baby, who have not participated in the decision not to have screening, still be entitled to therapy if the hydrops is caused by rhesus antibodies?
In view of the practical, economic, common sense and ethical problems of a potential voucher scheme it might be wise to shelve the idea in obstetrics until it has been tested in other areas such as chemotherapy for relapse of disseminated ovarian cancer.
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What do patients want from Medical research?
Robin Fox's splendid editorial (june 1996 jRSM, pp 301~2) stimulated me to a reprehensible practice-self-advertisement. A recent paper had asked the same important question', an earlier one? having proposed a new way to answer it which continues to engage our attention. In fact, more and more methods are being developed that not only allow clinicians to listen to their individual patients-" but also enable use to be made of what is learned in this way to treat the self-same individual. Such information about outcomes is also highly relevant to evidence-based medicine (EBM), and so may help to build a bridge between EBM and complementary methods. One of these is the subject of Andrew Vickers' excellent review in the same issue(pp 301--11).
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